Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Analgesic Treatment Mediated by Arcoxia (0663-093)

This study has been completed.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: September 22, 2006
Last updated: May 1, 2014
Last verified: May 2014

Allow physicians to test the efficacy of arcoxia in patients with acute pain.

Condition Intervention Phase
Drug: MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Analgesic Treatment Mediated by Arcoxia

Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Evaluate pain using the verbal analog scale (evaluate pain before starting treatment and then evaluate pain every day after had taken arcoxia up to three days)

Secondary Outcome Measures:
  • Patient satisfaction with the drug therapy using PGART scale
  • Patient satisfaction was obtained at the end of treatment(on third day)

Estimated Enrollment: 237
Study Start Date: April 2005

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of acute pain susceptible of pharmacological treatment
  • Greater than 18 years of age
  • Voluntary acceptance to participate in the study and signature of the informed consent form

Exclusion Criteria:

  • Allergy to etoricoxib or any of its components
  • Less than 18 years old
  • Patient is taking anticoagulants
  • Patient that already has taken any drug as analgesic
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00380523

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
  More Information

No publications provided

Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00380523     History of Changes
Other Study ID Numbers: 0663-093, 2006_034
Study First Received: September 22, 2006
Last Updated: May 1, 2014
Health Authority: Ecuador: Public Health Ministry processed this record on March 03, 2015